According tomedia reports, several new coronavirus vaccine candidates in laboratory tests are performing well, is currently at different stages of testing. Phases 1 and 2 trials are being conducted in several countries, including China, Germany, the United Kingdom and the United States, using a variety of vaccine technologies. Some of these vaccine candidates could be approved for emergency use as soon as this fall, including a breakthrough drug from Oxford University that already works in monkeys.
If the vaccine is safe for humans, as many as 30 million of AstraZeneca’s first 100 million doses in the UK could be available by September. The new coronal vaccine, developed by Oxford University, is called ChAdOx1 nCoV-19, which uses a weakened chimpanzee virus designed to carry the S protein of the SARS-CoV-2 virus. The idea is to inoculate the drug with patients to trigger an immune response that produces antibodies to the S protein. Once confronted with a truly new coronavirus, the body already has a way to block the protein from binding to human cells.
The researchers have explained that the six monkeys immunized with the candidate vaccine all produced antibodies that blockED SARS-CoV-2 from entering the cells and multiplying. The study also demonstrated that the drug is safe for animals because it does not lead to an increase in COVID-19 cases in subjects.
Oxford partnered with AstraZeneca to develop the drug, which began in mid-April, thanks to promising data from the monkey trials. British Commerce Secretary Alok Sharma told reporters on Sunday that plans were planned to roll out the COVID-19 vaccine to 30 million people by September, Sky News reported. Sharma said the Oxford study was “going well” but noted that there was no guarantee that the vaccine would work in humans.
“The first clinical trial of the Oxford vaccine went well, and all phase 1 participants received the vaccine dose as scheduled earlier this week,” he said. He added that AstraZeneca had finalised a “global licensing agreement” with Oxford University with government support.
“This means that if the vaccine is successful, AstraZeneca will try to provide 30 million doses of the vaccine to the UK by September, with a total dose of more than 100 million doses as part of the agreement.” “
If the vaccine is successful, 30 million doses of the vaccine will be enough to vaccinate nearly half of the UK population. By the time of writing, the number of confirmed cases of COVID-19 in the UK had exceeded 247,000, one of the highest in Europe, with 34,876 deaths. Sharma explained that the UK would be the first to get Oxford’s drugs, but that the government would ensure that “we can provide vaccines to developing countries at the lowest possible cost.”
Finally, the official said the UK’s first production innovation centre was expected to open in the summer of 2021, a year ahead of schedule. Once finalized, the centre will produce enough doses of the vaccine to serve the British public within six months. He said six drugs in the UK, in addition to the vaccine, had been put into clinical trials, and he explained that the vaccine might not be successful. That’s why we’re going to keep looking for other therapies. Imperial College London is also making “good progress” on vaccine candidates, with phase 1 trials due to begin in mid-June.